EUVIMEDEUVIMED entdecken
Crossref

Phase‐Separated Nano‐Antibiotics Enhanced Survival in Multidrug‐Resistant Escherichia coli Sepsis by Precise Periplasmic Ec DsbA Targeting

Pengfei Zou iD, Lin Huang, Yi Li, Dan Liu, Junwei Che, Te Zhao, Hui Li, Jiaxin Li, Ya-Nan Cui, Guobao Yang, Zhiping Li iD, Li-Li Li iD und 1 weitere

Advanced Materials · 2024-11 · 36 (44)

DOI: 10.1002/adma.202407152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 16.09.2024. Verfasst von Pengfei Zou und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Escherichia coli, Drug Resistance, Multiple, Bacterial, Sepsis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Science and Technologies Major Projects for "Major New Drugs Innovation and Development", Natural Science Foundation of Beijing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disulfide bond (Dsb) proteins, especially DsbA, represent a promising but as‐yet‐unrealized target in combating multidrug‐resistant (MDR) bacteria because their precise subcellular targeting through multibarrier remains a significant challenge. Here, a novel heterogenization‐phase‐separated nano‐antibiotics ( NCefoTs ) is proposed, through the co‐assembly of enzyme‐inhibiting lipopeptides (ELp component), membrane‐recognizing and disrupting lipopeptides (MLp component), and cefoperazone. The self‐sorting components of MLp “concentrated island‐liked clusters” on the surface of NCefoTs promote the efficient penetration of NCefoTs through the outer membrane. Triggered by the DsbA, the precisely spatiotemporal engineered NCefoTs transform to nanofibers in situ and further significantly enhance the inhibition of DsbA. The hydrolytic activity of β‐lactamase and the motility function of flagella are thereby impeded, confirming the efficacy of NCefoTs in restoring susceptibility to antibiotics and inhibiting infection dissemination. By these synergistic effects of NCefoTs , the minimum inhibitory concentration of antibiotics decreases from over 300 µM to 1.56 µM for clinically isolated E. coli MDR. The survival rate of sepsis‐inflicted mice is significantly enhanced from 0% to 92% upon encapsulation of cefoperazone in NCefoTs , which rapidly eliminates invading pathogens and mitigates inflammation. The universally applicable delivery system, based on an “on demands” strategy, presents a promising prospect for undruggable antibiotic targets in the periplasm to combat MDR bacteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsEscherichia coliDrug Resistance, Multiple, BacterialSepsisAnimalsMiceEscherichia coli InfectionsPeriplasmMicrobial Sensitivity TestsEscherichia coli ProteinsNanoparticles

Stichwörter der Autor:innen

DsbAantibiotic resistancein situ assemblylipopeptidesepsis

Substanzen

Anti-Bacterial AgentsEscherichia coli Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
  • School of Material Science and Engineering, Beijing Institute of Technology, Beijing, 100081, China.
  • CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, University of Chinese Academy of Sciences, Beijing, 100190, China.
  • School of Pharmacy, Henan University, Kaifeng, Henan, 475004, China.
  • School of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, Hebei, 050018, China.
  • School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, 250117, China.

ORCID-Profile: Pengfei Zou, Zhiping Li, Li-Li Li, Chunsheng Gao

Förderung

  • National Natural Science Foundation of China
  • National Science and Technologies Major Projects for "Major New Drugs Innovation and Development"
  • Natural Science Foundation of Beijing
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Zou, P., Huang, L., Li, Y., Liu, D., Che, J., Zhao, T., Li, H., Li, J., Cui, Y. N., Yang, G., Li, Z., Li, L. L., & Gao, C. (2024). Phase‐Separated Nano‐Antibiotics Enhanced Survival in Multidrug‐Resistant Escherichia coli Sepsis by Precise Periplasmic Ec DsbA Targeting. Advanced Materials, 36(44). https://doi.org/10.1002/adma.202407152

Vancouver

Zou P, Huang L, Li Y, Liu D, Che J, Zhao T, et al. Phase‐Separated Nano‐Antibiotics Enhanced Survival in Multidrug‐Resistant Escherichia coli Sepsis by Precise Periplasmic Ec DsbA Targeting. Advanced Materials. 2024;36(44). doi:10.1002/adma.202407152

BibTeX
@article{Zou2024,
  author = {Zou, Pengfei and Huang, Lin and Li, Yi and Liu, Dan and Che, Junwei and Zhao, Te and Li, Hui and Li, Jiaxin and Cui, Ya-Nan and Yang, Guobao and Li, Zhiping and Li, Li-Li and Gao, Chunsheng},
  title = {Phase‐Separated Nano‐Antibiotics Enhanced Survival in Multidrug‐Resistant Escherichia coli Sepsis by Precise Periplasmic Ec DsbA Targeting},
  journal = {Advanced Materials},
  year = {2024},
  volume = {36},
  number = {44},
  doi = {10.1002/adma.202407152}
}
Kostenlos starten →